AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15215800 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 2457
Study 15215800 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable coronary artery disease population
Number of subjects: 2457
Study 12236276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg four times daily for three days
Number of subjects: 78
Study 12236276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9846594 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with LCPUFA and vitamin E (FL)
Number of subjects: 49
Study 9846594 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented infant formula (F)
Number of subjects: 49
Study 9846594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FL and F)
Number of subjects: 49
Study 7813225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose biphasic oral contraceptive (25 micrograms desogestrel and 40 micrograms ethinylestradiol for 7 days, followed by 125 micrograms desogestrel and 30 micrograms ethinylestradiol for 15 days)
Number of subjects: 183
Study 7813225 — intervention group
Group type: COMPARATOR
Intervention: Diane-35 (2.0 mg cyproterone acetate and 30 micrograms ethinylestradiol for 21 days)
Number of subjects: 183
Study 2628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Centpropazine 120 mg and above
Number of subjects: 5
Study 2628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Centpropazine 40 mg daily
Number of subjects: 5
Study 2628304 — intervention group
Group type: EXPERIMENTAL
Intervention: Centpropazine 80 mg daily
Number of subjects: 5
Study 2628304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 624266 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 10
Study 624266 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 10
Study 624266 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOI
Number of subjects: 10
Study 624266 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOI plus L-tryptophan
Number of subjects: 10
Study 624266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31924256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial-point acupuncture
Number of subjects: 210
Study 31924256 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 210
Study 31924256 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation therapy
Number of subjects: 210
Study 30221775 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time auditory feedback during knee repositioning task
Number of subjects: 30
Study 30221775 — intervention group
Group type: COMPARATOR
Intervention: No auditory feedback (Control)
Number of subjects: 30
Study 30221775 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time auditory feedback
Number of subjects: 30
Study 28045285 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 163
Study 28045285 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 163
Study 25547237 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral volar static wrist and MCP splint
Number of subjects: 54
Study 25547237 — intervention group
Group type: COMPARATOR
Intervention: Neutral volar static wrist splint
Number of subjects: 54
Study 23609203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 100
Study 23609203 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 16908730 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (100 mug/kg bolus followed by 1 mug/kg/min infusion for 48 hours) combined with intravenous rtPA
Number of subjects: 15
Study 15853274 — intervention group
Group type: COMPARATOR
Intervention: Single visit endodontic procedure
Number of subjects: 0
Study 15853274 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple visits endodontic procedure
Number of subjects: 0
Study 15853274 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with vital pulps
Number of subjects: 0
Study 15853274 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth with non-vital pulps
Number of subjects: 0
Study 10715521 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 299
Study 10715521 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 299
Study 10715521 — intervention group
Group type: EXPERIMENTAL
Intervention: pa vaccine
Number of subjects: 299
Study 8857658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular infiltration
Number of subjects: 89
Study 8857658 — intervention group
Group type: COMPARATOR
Intervention: Mandibular block
Number of subjects: 89
Study 1727801 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 96
Study 1727801 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal transection
Number of subjects: 96
Study 1727801 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 96
Study 1727801 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 96
Study 6716325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego threat
Number of subjects: 0
Study 6716325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor
Number of subjects: 0
Study 6716325 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study 31529471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil 5% cream
Number of subjects: 624
Study 31529471 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod 5% cream
Number of subjects: 624
Study 31529471 — intervention group
Group type: COMPARATOR
Intervention: Methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 624
Study 31529471 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate 0.015% gel
Number of subjects: 624
Study 29426695 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 4282
Study 29426695 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted Charlson score of 5 or higher
Number of subjects: 4282
Study 29426695 — intervention group
Group type: EXPERIMENTAL
Intervention: Small subgroups (1-5%)
Number of subjects: 4282
Study 29426695 — intervention group
Group type: COMPARATOR
Intervention: PIVOT results
Number of subjects: 4282
Study 28888286 — intervention group
Group type: EXPERIMENTAL
Intervention: Information treatment about funding opportunities for, and returns to, higher education (25-minute session)
Number of subjects: 0
Study 28888286 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26094929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg eszopiclone per day
Number of subjects: 78
Study 24054897 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole with a lateral wedge and additional off‐the‐shelf anti‐pronatory support
Number of subjects: 15
Study 24054897 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole with a lateral wedge with no additional support
Number of subjects: 15
Study 24054897 — intervention group
Group type: COMPARATOR
Intervention: Control condition (with standard shoes)
Number of subjects: 15
Study 20970173 — intervention group
Group type: EXPERIMENTAL
Intervention: Stone Cone
Number of subjects: 195
Study 20970173 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐Trap
Number of subjects: 195
Study 20970173 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic lithotripsy without any ureteral occlusive device (Control Group)
Number of subjects: 195
Study 19700984 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (BTX‐A)
Number of subjects: 20
Study 19700984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16036211 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive imagery of an animal with a coloured object
Number of subjects: 0
Study 16036211 — intervention group
Group type: COMPARATOR
Intervention: Imagining scenes where the animal and coloured object were independent
Number of subjects: 0
Study 12631596 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO-PCV
Number of subjects: 249
Study 12631596 — intervention group
Group type: COMPARATOR
Intervention: PCV
Number of subjects: 249
Study 10854004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oestrogen replacement therapy (ERT) 0.625 mg/day
Number of subjects: 17
Study 10854004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oestrogen and progestogen replacement therapy (HRT) ERT plus continuous medroxyprogesterone acetate 5 mg/day
Number of subjects: 17
Study 10854004 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study 8884295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube splinting (group B)
Number of subjects: 56
Study 8884295 — intervention group
Group type: COMPARATOR
Intervention: No tube splinting (group A)
Number of subjects: 56
Study 1544194 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.5 MAC, 1.0 MAC, or 1.5 MAC (randomized initial concentration)
Number of subjects: 32
Study 1544194 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC over 90 to 150 min
Number of subjects: 32
Study 4007193 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% homologous patient serum
Number of subjects: 100
Study 4007193 — intervention group
Group type: COMPARATOR
Intervention: Fetal cord serum
Number of subjects: 100
Study 31355944 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg administered for twelve weeks
Number of subjects: 31
Study 31355944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29355398 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in using Twitter strategically
Number of subjects: 3
Study 26107849 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy measured from intracardiac recordings at the right atrium (RA)
Number of subjects: 31
Study 26107849 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy measured from intracardiac recordings at the left atrium (LA)
Number of subjects: 31
Study 26107849 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy values at the right atrium (RA)
Number of subjects: 31
Study 25233383 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 211
Study 25233383 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line invasive mechanical ventilation
Number of subjects: 211
Study 25233383 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation
Number of subjects: 211
Study 22658954 — intervention group
Group type: EXPERIMENTAL
Intervention: SEEK model of enhanced pediatric primary care
Number of subjects: 1119
Study 22658954 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1119
Study 20615889 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intervention
Number of subjects: 350
Study 20615889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 18024869 — intervention group
Group type: EXPERIMENTAL
Intervention: Four additional cycles of third-generation, platinum-doublet treatment (arm A)
Number of subjects: 314
Study 18024869 — intervention group
Group type: COMPARATOR
Intervention: Two additional cycles of third-generation, platinum-doublet treatment (arm B)
Number of subjects: 314
Study 16209966 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5-10 mg)
Number of subjects: 203
Study 16209966 — intervention group
Group type: COMPARATOR
Intervention: Losartan (25-50 mg)
Number of subjects: 203
Study 12585142 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyu Tablet (XYT)
Number of subjects: 20
Study 12585142 — intervention group
Group type: COMPARATOR
Intervention: Gastrodine lipid-lowering tablet
Number of subjects: 20
Study 10512389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular long‐bar overdenture
Number of subjects: 16
Study 10512389 — intervention group
Group type: COMPARATOR
Intervention: Hybrid overdenture
Number of subjects: 16
Study 7862416 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS) Plus
Number of subjects: 64
Study 7862416 — intervention group
Group type: COMPARATOR
Intervention: Dextrose bicarbonate lactated Ringer's solution
Number of subjects: 64
Study 1772464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite (2 tablets qid, neutralizing capacity 122 mmol)
Number of subjects: 12
Study 1772464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7019454 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine with cerium nitrate
Number of subjects: 2
Study 7019454 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine alone
Number of subjects: 2
Study 31604061 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hyaluronic acid (8 mL, range 4 to 11 mL)
Number of subjects: 30
Study 31604061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 31604061 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of hyaluronic acid
Number of subjects: 30
Study 31180160 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex abutment (CX Group)
Number of subjects: 28
Study 31180160 — intervention group
Group type: COMPARATOR
Intervention: Concave abutment (CV Group)
Number of subjects: 28
Study 27684740 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended flexible regimen of 20 μg ethinylestradiol and 3 mg drospirenone (EE/DRSPe.flex)
Number of subjects: 0
Study 27684740 — intervention group
Group type: COMPARATOR
Intervention: 24/4 cyclical regimen of the same formulation (EE/DRSP24/4)
Number of subjects: 0
Study 25711648 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychiatric management (10-session treatment)
Number of subjects: 1
Study 23612465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 3206
Study 23612465 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 3206
Study 23612465 — intervention group
Group type: EXPERIMENTAL
Intervention: FNAB
Number of subjects: 3206
Study 23612465 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for benign lesions
Number of subjects: 3206
Study 23612465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3206
Study 21159080 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned card
Number of subjects: 1506
Study 21159080 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre-based education
Number of subjects: 1506
Study 21159080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 1506
Study 21159080 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1506
Study 19808441 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (1 g of cefazolin administered intravenously before the procedure)
Number of subjects: 1000
Study 19808441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no antibiotics administered)
Number of subjects: 1000
Study 17401033 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments (extra visit at week 3)
Number of subjects: 41
Study 17401033 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments (extra visit at week 5)
Number of subjects: 41
Study 17401033 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional follow-up visits
Number of subjects: 41
Study 17401033 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 41
Study 17401033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 14971661 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble nickel compounds (Ni3S2, NiS, HT NiO, LT NiO)
Number of subjects: 0
Study 11252686 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 600
Study 11252686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg TID
Number of subjects: 600
Study 11252686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 9448064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroacetate (DCA) administered to healthy volunteers, specific dosage not mentioned.
Number of subjects: 0
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 micrograms kg‐1 (group A)
Number of subjects: 157
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms kg‐1 (group B)
Number of subjects: 157
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1 (group C)
Number of subjects: 157
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (any dose) with rescue doses
Number of subjects: 157
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron alone (any dose)
Number of subjects: 157
Study 8180032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 157
Study 3358901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg 12 hourly
Number of subjects: 9
Study 3358901 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg 8 hourly
Number of subjects: 9
Study 3358901 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 125 mg 8 hourly
Number of subjects: 9
Study 29216020 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-pHF (1.9 g protein/100 kcal)
Number of subjects: 402
Study 29216020 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-eHF with synbiotics
Number of subjects: 402
Study 29216020 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-pHF with synbiotics
Number of subjects: 402
Study 29216020 — intervention group
Group type: COMPARATOR
Intervention: Regular protein eHF (2.3 g protein/100 kcal)
Number of subjects: 402
Study 29216020 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-eHF
Number of subjects: 402
Study 28044986 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month dual antiplatelet therapy (DAPT)
Number of subjects: 587
Study 28044986 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 587
Study 26136531 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10
Study 26136531 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 26136531 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (control experiments without GLP-1)
Number of subjects: 10
Study 26136531 — intervention group
Group type: COMPARATOR
Intervention: Saline (control experiments without GLP-1)
Number of subjects: 10
Study 23785166 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg)
Number of subjects: 0
Study 23785166 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (50 mg)
Number of subjects: 0
Study 23785166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21131461 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine topical anesthetic cream applied to the face for one hour without occlusion (Group A)
Number of subjects: 25
Study 21131461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one half-hour without occlusion (Group B)
Number of subjects: 25
Study 21131461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one hour without occlusion (Group C)
Number of subjects: 25
Study 21131461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of 4% lidocaine applied to the face for one hour with occlusion (Group D)
Number of subjects: 25
Study 21131461 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all four groups
Number of subjects: 25
Study 18992629 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient and outpatient counseling on smoking cessation and pharmacological protocol
Number of subjects: 277
Study 18992629 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 277
Study 16361531 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC50 plus tamoxifen (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2, six cycles every 21 days)
Number of subjects: 457
Study 16361531 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (30 mg/day, 3 years)
Number of subjects: 457
Study 16361531 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC50 plus tamoxifen
Number of subjects: 457
Study 16361531 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 457
Study 12652882 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous video
Number of subjects: 33
Study 12652882 — intervention group
Group type: COMPARATOR
Intervention: Distraction control group (tourism video)
Number of subjects: 33
Study 10645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic processing
Number of subjects: 0
Study 10645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked presentation of target items
Number of subjects: 0
Study 10645381 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention interval (immediate, one week, three weeks)
Number of subjects: 0
Study 10645381 — intervention group
Group type: COMPARATOR
Intervention: Nonsemantic processing
Number of subjects: 0
Study 8703299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic doses)
Number of subjects: 15
Study 8703299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1810331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Silver (1 mm placed on the axial wall before amalgam insertion)
Number of subjects: 50
Study 1810331 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Lining/amalgam
Number of subjects: 50
Study 1810331 — intervention group
Group type: EXPERIMENTAL
Intervention: Miracle Mix/amalgam
Number of subjects: 50
Study 1810331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersalloy amalgam alone
Number of subjects: 50
Study 1810331 — intervention group
Group type: COMPARATOR
Intervention: No restorations
Number of subjects: 50
Study 6409690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg three times a day)
Number of subjects: 25
Study 6409690 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g three times a day)
Number of subjects: 25